Trials / Completed
CompletedNCT05275855
First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers
A First-in-human, Randomized, Participant and Investigator Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of EDI048 administered orally in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDI048 | Oral Liquid |
| OTHER | Placebo | Oral Liquid |
Timeline
- Start date
- 2022-04-29
- Primary completion
- 2024-12-18
- Completion
- 2024-12-18
- First posted
- 2022-03-11
- Last updated
- 2025-01-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05275855. Inclusion in this directory is not an endorsement.